Clinical Trial

Inaticabtagene Autoleucel Injection in the Treatment of Autoimmune Hemolytic Anemia After Three or More Lines of Therapy

Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a multicenter, open-label, single-arm Phase I clinical trial to evaluate the safety and tolerability of Inaticabtagene Autoleucel Injection treatment in autoimmune hemolytic anemia that has failed at least three lines of treatment.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-07-21; most recent amendment 2025-09-17.
Trial Details
NCT Number NCT07091370
Lead Sponsor Juventas Cell Therapy Ltd.
Conditions AIHA - Cold Autoimmune Hemolytic Anemia
Enrollment 12 participants
Start Date 2025-12-27
Primary Completion 2026-09-30 (estimated)
Study Completion 2028-03-30 (estimated)
Updated on ClinicalTrials.gov 2025-09-22